Phase 3 N=861 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Stage IV Pancreatic Cancer
Primary: Complete Response Rate — 2; 15; 4; 3 Participants
Phase 2 N=20 Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
Pancreatic Cancer
Primary: Overall Survival Rate at 6 Months — 58 percentage of participants
Phase 2 N=40 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Phase 2 N=42 Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Primary: 12- Month Overall Survival (OS) — 16 Participants
Phase 3 N=211 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival — 6.4; 5.9 months
Phase 2 N=25 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Phase 2 N=48 ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
Phase 2 N=127 FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization — 28; 14 Participants
Phase 2 N=36 Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
Pancreatic Cancer
Primary: Overall Survival Rate at 6 Months — 8 participants
Phase 2 N=50 BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Metastatic Pancreatic Cancer
Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months
Phase 2 N=16 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
Pancreatic Cancer · Pancreatic Ductal Adenocarcinoma · Pancreatic Adenocarcinoma
Primary: Best Overall Response (BOR) — 0; 0; 3; 11 Participants
Phase 2 N=104 Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 4.2; 8.3 months — p=0.36
Phase 2 N=8 AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pancreatic Neoplasms
Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026
Phase 2 N=19 Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage IV Pancreatic Cancer
Primary: Six Month Survival — 11 percentage of patients
Phase 2 N=20 Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: 2-month Progression-Free Survival Rate — 10; 10 percentage of patients
Phase 2 N=180 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Overall Survival — 8.8; 9.8 months — p=0.72
Phase 2 N=50 Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival — 5.7 months
Phase 2 N=10 Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL
Phase 2 N=67 Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 4; 0; 1 participants
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Phase 2 N=32 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
Resectable Pancreatic Cancer · Unresectable Pancreatic Cancer · Pancreatic Adenocarcinoma
Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235
Phase 2 N=30 Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
Pancreatic Cancer
Primary: Progression Free Survival — 2.07 months
Phase 2 N=33 RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy. — 23…
Phase 2 N=77 MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Pancreatic Cancer · Pancreatic Adenocarcinoma
Primary: MK-0646 Maximum Tolerable Dose — 0; 0; 0; 2 participants
Phase 2 N=44 Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival — 3.9 months
Phase 2 N=35 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Complete Response Rate — 21; 9; 2 Participants
Phase 2 N=137 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
Pancreatic Acinar Cell Carcinoma · Pancreatic Ductal Adenocarcinoma · Recurrent Pancreatic Carcinoma
Primary: Overall Survival — 6.7; 3.9 months — p=0.15
Phase 2 N=21 Cabozantinib and Pembrolizumab in Metastatic Pancreas
Pancreatic Cancer
Primary: Progression-free Survival — 2 Participants
Phase 2 N=61 Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Response Rate (ORR) — 6.9 percentage of participants